Iain Thomas

Iain is the Head of the Life Sciences Technology Transfer team at Cambridge Enterprise. The team commercialises technology in a wide variety of fields, from agri-tech to therapeutics. Recent spin-outs from the University of Cambridge (UoC) include Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor, Phoremost and Predictimmune.  XO1 was sold to Janssen for an undisclosed sum.

Iain has led discussions with GSK on the UoC–GSK open innovation drug discovery initiative, based at the Stevenage Bioscience Catalyst. He helped co-found Apollo Therapeutics, an innovative vehicle for developing early stage therapeutic opportunities from UoC, University College London and Imperial College, and led the creation of the Ceres Agri-Tech Knowledge Exchange Partnership. Iain is also a member of the Ceres Management Committee.